

Daiichi Sankyo Selected for Dow Jones Sustainability Asia Pacific Index for Third Consecutive Year

September 26, 2012, TOKYO, JAPAN – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has been selected for the third consecutive year for the Dow Jones Sustainability Index.

Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indexes (DJSI) is one of the leading indexes for Socially Responsible Investment (SRI)*. DJSI is the global index from Dow Jones of the USA and Sustainable Asset Management (SAM) of Switzerland, which assesses and selects leading, sustainability-driven companies worldwide in terms of economic, environmental and social performance. These are an important investment standard for investors who have an interest in corporate social responsibility (CSR). The DJSI Asia Pacific has selected the top 154 regional sustainability leaders, including 74 Japanese companies, out of 600 leading companies from developed markets in Asia Pacific.

As a company trusted by stakeholders who have a vested interest in its sustained growth and success, Daiichi Sankyo will continue to make every effort to enhance “corporate quality” and put into practice its mission, which is, “To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.”

* An investment based on criteria that assess a company’s social responsibility performance from environmental, social and other perspectives, in addition to financial analysis.



About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

FOR MORE INFORMATION

Daiichi Sankyo

Noriaki Ishida, Corporate Communications Department

Telephone: +81-3-6225-1126

Daiichi Sankyo, Inc.

Marah Binder, Public Affairs

Telephone: 973.944.2253